Compass Pathways plc CMPS
Compass Pathways plc (Nasdaq: CMPS) is a CNS/neurology/psychiatry drug developer. Its lead program, COMP360 psilocybin, is in Phase 3 for Treatment-resistant depression (TRD). Its next catalyst on record is COMP360 TRD: Potential commercial launch if approved (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: COMP360 TRD — Potential commercial launch if approved (2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| COMP360 psilocybin | Treatment-resistant depression (TRD) | small molecule | Phase 3 |
| COMP360 psilocybin | Post-traumatic stress disorder (PTSD) | small molecule | Phase 2 |
Recent results and decisions
- Nov 3, 2026submitted Compass Pathways nearing completion of rolling NDA submission for COMP360 in TRD, with final submission expected within two weeks.
Rolling New Drug Application (NDA) submission nearing completion, with rolling review underway. Final NDA submission will be filed in the next two weeks
Filing - Nov 3, 2026positive COMP005 52-week open label data showed notable added benefit from an additional COMP360 25 mg dose extending durability out to one year.
52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year
Filing - Nov 3, 2026started Late-stage PTSD trial designed to be registration-enabling is ongoing for COMP360.
Late-stage PTSD trial, designed to be registration-enabling underway
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.